Physician profile
Amjad Iqbal
NPI 1942209168
$6,820.46
in general payments reported to CMS, 2019-2025
34 companies · $914 in 2025
The $914 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $730 · 2021: $785 · 2022: $832 · 2023: $1,133 · 2024: $1,212 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,259.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $944.02 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $787.76 | 2019-2025 | |
| Amarin Pharma, INC. | $681.30 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $600.19 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $515.96 | 2019-2024 | Xarelto |
| Pfizer INC. | $447.12 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $373.17 | 2019-2025 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $363.56 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $359.32 | 2019-2025 | Eliquis, Camzyos |
| Azurity Pharmaceuticals, INC. | $217.16 | 2023-2025 | Edarbyclor, Edarbi, Edarbi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.27 | 2019-2022 | |
| Esperion Therapeutics, INC. | $144.40 | 2021-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $132.51 | 2019-2021 | |
| Astellas Pharma US INC | $117.24 | 2019-2022 | |
| Philips North America LLC | $114.21 | 2020-2024 | (Ck4) Mcot |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $112.54 | 2024-2025 | |
| Arbor Pharmaceuticals, INC. | $104.99 | 2019-2022 | |
| Novo Nordisk INC | $87.36 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $76.69 | 2023-2025 | Watchman Access System, Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $73.27 | 2019 | |
| Bridgebio Pharma, INC. | $57.55 | 2025 | Attruby |
| Scpharmaceuticals INC. | $35.46 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $32.17 | 2024 | Arcalyst |
| Otsuka America Pharmaceutical, INC. | $30.71 | 2025 | Rexulti |
| Genzyme Corporation | $28.13 | 2019-2023 | |
| Abiomed | $23.96 | 2024 | Impella |
| Edwards Lifesciences Corporation | $23.17 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Atricure, INC. | $22.95 | 2025 | Synergy Ablation System |
| Cvrx, INC. | $20.77 | 2023 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $20.66 | 2024 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $18.73 | 2023 | Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $16.66 | 2023 | Arcalyst |
| Vifor Pharma, INC. | $12.71 | 2019 | |
| Biotronik INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amjad Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.